

1 Invitation for adults (≥18 years old) to participate in the study

2 **Living with Primary Ciliary Dyskinesia (PCD)**

3

4 **Dear study participant,**

5 Thank you for considering taking part in this online study which describes health, health care, and
6 psychosocial aspects of **children and adults who have PCD**. Your participation is entirely voluntary.
7 All data collected as part of this research project will be stored safely as we explain in detail in this
8 information sheet.

9 The chief investigator of this project is Prof. Claudia Kuehni at the Institute of Social and Preventive
10 Medicine in Bern (Switzerland).

11 **What is the study about and why do we do it?**

12 The study aims to increase knowledge about PCD in order to improve the health and quality of life of
13 people with PCD. The study started in 2020 when PCD patient support groups asked for a study that
14 finds out what happens to people with PCD during the COVID-19 pandemic. After the pandemic, with
15 the continuous encouragement of PCD patient support groups, we want to continue to learn more about
16 other important topics for people living with PCD, such as lung health, mental health, or treatment
17 burden by obtaining regular updates via online questionnaires.

18 **Who can participate?**

19 Everybody with a confirmed diagnosis of PCD or a clinical suspicion of PCD can take part. Patient
20 support groups from all over the world support the study. Parents of a child with PCD can take part in
21 the study and fill in the study questionnaires with their child.

22 **Are there any benefits or risk for me taking part?**

23 **Benefits**

- 24 • There are no direct benefits for you if you take part, but people with PCD may profit in the future.
- 25 • You have easy access to our study website where we will regularly publish updates on our
- 26 results using simple language so that you will be informed first hand.
- 27 • You can also suggest topics to be investigated in the future.

28 **Risks and inconveniences**

- 29 • There is no risk nor major inconveniences of taking part in this study.

30

31 Goal and general information

32 Living with PCD is an international online study hosted in Bern, Switzerland. The goal of the study is to
33 increase knowledge about PCD to improve the health and quality of life, such as lung health, mental
34 health and treatment burden. Our current research priorities include physical symptom evolution over
35 time, seasonal changes in symptoms, mental health and social functioning, treatment burden, nutrition,
36 fertility concerns and subsequent reproductive success rates. Every person with a confirmed or
37 suspected diagnosis of PCD or a parent of a child with PCD is invited to participate.

38 This research project is conducted in compliance with Swiss legislation and international guidelines.
39 The research project has been reviewed and authorized by the competent ethics committee.

40 What data will be collected?

41 We need an email address to send you a link to access the online questionnaires. The email address
42 is stored separately and will never be given out.

- 43 • **At the start we will send you the link to a baseline questionnaire** which asks about your disease,
44 your “normal” symptoms, your treatments, health-related behaviours (e.g. exercise), and some
45 general information about your family. This comprehensive questionnaire allows us to gain a clear
46 overall understanding of your situation.
- 47 • **Then we will send you follow-up questionnaires** which ask again about your current symptoms
48 and treatments (planned 1x per year). This helps us understand how PCD changes over time.

49 **Extra questionnaires**, from time to time (approximately two times a year), will deal with **special topics**.
50 For instance: physical activity, mental health, nutrition. You can also suggest topics to be included in
51 extra questionnaires and thus help to shape the study. For all questionnaires, you are encouraged to
52 reply all questions, but you can also select to skip some if you would not like to answer.

53 How long does the study last?

54 The study has a provisional end date at the end of 2030. However, this date might be extended,
55 depending on funding and interest by the participants. If so, you will be informed. But you can withdraw
56 any time and tell us that you don't want to receive more emails.

57 Are there any advantages for me if I participate in the study, and are there any risks?

58 There are no direct personal benefits from participating in the study, but your participation will help to
59 better understanding of PCD and may benefit others with the condition in the future. You will have direct
60 access to our study website with the latest results and will be informed first-hand. You can also suggest
61 topics to be explored in a future questionnaire. There are no direct risks or physical procedures involved
62 in this study.

63 What happens with the data that I provide for this study, and when will I get information about 64 the results?

65 We will analyse data regularly, publish it online on our study website, and make it available to people
66 with PCD, doctors and policy makers. The data will also be published in scientific journals and via the
67 PCD support groups.

68 Will my data be kept confidential?

69 With the exception of e-mails (compulsory), we will not collect any personal or identifying data. Only
70 members of the research team will see your email address, and only to perform tasks related to the
71 project. All data is saved using the secure, web-based application, Research Electronic Data Capture
72 (REDCap), which is a tool to collect and save data for research. The database is run by the SwissRDL,
73 a centre for medical registries and data linkage at the University of Bern. Your health-related data can
Information and consent form for adults (≥18 years old)

be given to other research groups, also abroad, but always encrypted, so that it is not possible to identify you. Encryption means that all data that can identify you (email address) is deleted and replaced with an encryption code. No data in any publication will be traceable to you as an individual. All research personnel who have access to your data as part of this project are subject to confidentiality. The requirements of data protection are complied with, and you, as a participant, have the right to inspect your data at any time.

Do I have to take part in the study, and what happens if I change my mind?

It is your free decision whether you want to take part in the study. You may choose to skip certain extra questionnaires that you do not want to complete. You can also change your mind and withdraw at any time without giving a reason. To withdraw your consent and step out of the study, you can write an email to pcd.ispm@unibe.ch. We will then no longer send you questionnaires and you choose if you want us to anonymise or delete your already collected data.

Who has reviewed this study?

The patient support groups that are supporting the study have contributed to the design of this study and have approved it, and the ethics committee of the canton of Bern, Switzerland has reviewed and approved this study (2025-00807).

This project may be reviewed by the responsible ethics committee (if needed) and by the organisation that is funding or supporting the study. If that happens, the researcher may need to share the stored data. Everyone involved is required to keep your information strictly confidential.

Financing

The study is supported by grants from the Swiss National Science Foundation (10001934, 320030B_192804). We have also received funding from the Swiss Lung League, and from various PCD patient support groups (PCD Support UK, PCD Foundation, PCD Australia, Kartagener Syndrom und Primäre Ciliäre Dyskinesie e. V.).

Where can I get more information?

More information and first results are available on the study website www.pcd.ispm.ch. You can also contact the PCD support group in your country, and the research team at the Institute of Social and Preventive Medicine, University of Bern, Switzerland by phone +41 31 684 68 55 or by email to pcd.ispm@unibe.ch. Dr. Myrofora Goutaki, and Prof. Claudia Kuehni will answer your questions.

You can also watch a video with the study information available on the study website.

104
105
106
107
108
109

Consent form for adults (≥18 years old)

Please read this form carefully. Don't hesitate to contact us if there is anything you do not understand or if you have questions about the study. By selecting "yes" for the checkboxes below, you confirm your voluntary participation and that you have read and understood the information provided in this document. Your informed consent to all points below is required for participation.

Yes No

- I confirm that I have read the study information for the study Living with PCD (2025-00807). ☐ Yes ☐ No
- I understand that my participation is voluntary and that I am free to withdraw from the study at any time, without giving any reason. If I withdraw from the study, I will get no more links to questionnaires and I can choose if my data will be anonymised or deleted, after the data has been analysed. ☐ Yes ☐ No
- I understand that data collected from this study may be accessed by research staff from the Institute of Social and Preventive Medicine, University of Bern, Switzerland. ☐ Yes ☐ No
- I understand that data collected from this study will be analysed and published using encrypted data and results can be shared with other researchers, regulatory bodies, or public health agencies. My health-related data can be given to other research groups, also abroad, but always encrypted. ☐ Yes ☐ No
- I agree that emails with a weblink to questionnaires will be sent to the email address that I provided until the study ends or I request to withdraw from the study. I will be free to skip some questionnaires if I don't have time or prefer not to answer. ☐ Yes ☐ No
- I understand that the data collected will be held and maintained by the Institute of Social and Preventive Medicine, University of Bern, for a minimum of 15 years. ☐ Yes ☐ No
- I agree to take part in this study. ☐ Yes ☐ No

110
111

Date: